ZYMEZymeworks Inc.

ZYME Stock Price, Valuation & Chart | Zymeworks Inc.

Compare

$31.050+1.38 (+4.65%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ZYME intrinsic value ZYME calculated fair value vs price

Overview Financials Dividends Ratios

ZYME Historical price chart

ZYME Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.28B

PE Ratio-15.37

EPS-2.02

Trading Volume646.37K

Today's High/Low31.17/30.0

Dividend Yield0.00

52 Week High/Low31.17/13.6

Shares Outstanding73.57M

ZYME Financial Statement

ZYME Analyst ratings

ZYME Analysis & performance metrics

ZYME Company profile

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product…

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49,…

ZYME Management team

Name

Position

Paul A. Moore Ph.D.

Chief Scientific Officer

Lindsey Foulkes B.Sc., Ph.D.

Vice President of Corporate Development

Leone D. Patterson CPA, M.B.A.

Executive Vice President and Chief Business & Financial Officer

Mark Hollywood

Executive Vice President and Head of Technical & Manufacturing Operations

Daniel Dex J.D., Ph.D.

Senior Vice President, Corporate Secretary & General Counsel

Jeffrey Smith M.D.

Executive Vice President & Chief Medical Officer

Shrinal InamdarCTO

Director of Investor Relations

Diana Papove

Senior Manager of Corporate Communications

Name

Position

Paul A. Moore Ph.D.

Chief Scientific Officer

Lindsey Foulkes B.Sc., Ph.D.

Vice President of Corporate Development

Leone D. Patterson CPA, M.B.A.

Executive Vice President and Chief Business & Financial Officer

Mark Hollywood

Executive Vice President and Head of Technical & Manufacturing Operations

Daniel Dex J.D., Ph.D.

Senior Vice President, Corporate Secretary & General Counsel

Jeffrey Smith M.D.

Executive Vice President & Chief Medical Officer

Shrinal InamdarCTO

Director of Investor Relations

Diana Papove

Senior Manager of Corporate Communications

Management Team

Paul A. Moore Ph.D.

Chief Scientific Officer

Lindsey Foulkes B.Sc., Ph.D.

Vice President of Corporate Development

Leone D. Patterson CPA, M.B.A.

Executive Vice President and Chief Business & Financial Officer

Mark Hollywood

Executive Vice President and Head of Technical & Manufacturing Operations

Daniel Dex J.D., Ph.D.

Senior Vice President, Corporate Secretary & General Counsel

Jeffrey Smith M.D.

Executive Vice President & Chief Medical Officer

Shrinal InamdarCTO

Director of Investor Relations

Diana Papove

Senior Manager of Corporate Communications

Management

Paul A. Moore Ph.D.

Chief Scientific Officer

Lindsey Foulkes B.Sc., Ph.D.

Vice President of Corporate Development

Leone D. Patterson CPA, M.B.A.

Executive Vice President and Chief Business & Financial Officer

Mark Hollywood

Executive Vice President and Head of Technical & Manufacturing Operations

Daniel Dex J.D., Ph.D.

Senior Vice President, Corporate Secretary & General Counsel

Jeffrey Smith M.D.

Executive Vice President & Chief Medical Officer

Shrinal InamdarCTO

Director of Investor Relations

Diana Papove

Senior Manager of Corporate Communications

Total 8 executives

ZYME Frequently asked questions

What is Zymeworks Inc. (ZYME) Stock Price?

Current stock price of Zymeworks Inc. (ZYME) stock is $31.050. The stock price is +4.65% higher in the session. The intraday range can be seen from this page. Volume of Zymeworks Inc. (ZYME) stock is 646.37K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Zymeworks Inc. (ZYME) stock price going up or down today?

The stock price of Zymeworks Inc. (ZYME) can change with earnings, company news, and overall market sentiment. Zymeworks Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Zymeworks Inc. stock expensive at its current price?

Whether Zymeworks Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ZYME on this page is -15.37. EPS on this page is -2.02. Compare those figures with peers and growth expectations before deciding if the current Zymeworks Inc. price is justified.

How has the stock price of Zymeworks Inc. (ZYME) performed historically?

Historical performance for Zymeworks Inc. (ZYME) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ZYME reacted to past earnings and market events.

Should I buy Zymeworks Inc. (ZYME) stock, at this price?

Buying Zymeworks Inc. (ZYME) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.